Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460

Kubo, Nobuteru; Noda, Shin‐ei; Takahashi, Akihisa; Yoshida, Yukari; Oike, Takahiro; Murata, Kazutoshi; Musha, Atsushi; Suzuki, Yoshiyuki; Ohno, Tatsuya; Takahashi, Tetsuya; Nakano, Takashi

doi:10.1093/jrr/rru085

Cited by 29 publications

(23 citation statements)

References 36 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These favorable LC rates may be attributable to a biological advantage of C‐ion RT and a radiosensitizing effect of cisplatin to C‐ion beam irradiation. Recent in vitro studies have demonstrated that the addition of chemotherapeutic drugs to C‐ion RT is a potential method for enhancing its efficacy. Meanwhile, few studies have investigated the radiosensitizing effect of cisplatin to C‐ion beam irradiation in cervical cancer cell lines.…”

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001)

et al. 2018

Self Cite

View full text Add to dashboard Cite

We conducted a phase 1/2 study to evaluate the efficacy and safety of carbon ion radiotherapy (C‐ion RT) with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma. Thirty‐three patients were enrolled between April 2010 and March 2014. Treatment consisted of C‐ion RT with concurrent weekly cisplatin at a dose of 40 mg/m2. In the phase 1 component, the total dose was escalated from 68.0 Gy (relative biological effectiveness [RBE]) to 74.4 Gy (RBE) to determine the maximum tolerated dose of C‐ion RT. In the phase 2 component, the efficacy and safety of C‐ion RT with concurrent chemotherapy were evaluated using the dose determined in the phase 1 component. The median follow‐up duration was 30 months. Two patients did not receive chemotherapy because of anemia or leukocytopenia immediately prior to commencing treatment; 31 patients were analyzed. None of the patients developed dose‐limiting toxicities. The recommended dose (RD) was determined to be 74.4 Gy (RBE). In the phase 2 component, two patients developed Grade 3–4 toxicities in the gastrointestinal tract, due to repeated laser coagulation or peritonitis caused by appendicitis. In the patients treated with the RD, the 2‐year local control, progression‐free survival, and overall survival rates were 71%, 56%, and 88%, respectively. C‐ion RT with concurrent weekly cisplatin was well tolerated in patients with locally advanced uterine cervical adenocarcinoma. Our findings support further investigations into the efficacy of this strategy.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001)

et al. 2018

Self Cite

View full text Add to dashboard Cite

show abstract

“…Recently, 12 C 6þ radiotherapy, as a highly intensive local therapy, has become one of the most used therapeutic strategies for various malignancies. Compared to conventional photon and proton irradiation, 12 C 6þ radiotherapy induces a stronger lethal effect on cancer cells due to the unique physical and biological effects, including superior physical dose distribution (spread-out Bragg peak) [5], smaller volume of irradiated normal tissue [6], higher relative biological effectiveness, lower oxygen enhancement ratio, unrepaired DNA damage and nearly unchanged radio-sensitivity within the cell cycle [7][8][9]. This results in a cell-killing effect that is two to three times greater than that of X-rays [5,10].…”

Section: Introductionmentioning

confidence: 99%

Inhibition of Wnt signalling pathway by XAV939 enhances radiosensitivity in human cervical cancer HeLa cells

Zhang

Gan

et al. 2020

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Cervical cancer is the second most common malignant tumour threatening women's health. In recent years, heavy-ion beam therapy is becoming a newly emerging therapeutic mean of cancer; however, radio-resistance and radiation-induced damage constitute the main obstacles for curative treatment of cervical cancer. Therefore, to identify the radiosensitizers is essential. Here, we investigated the effects of Wnt signalling pathway on the response of 12 C 6þ radiation in HeLa cells. XAV939, an inhibitor of Wnt signalling pathway, was added two hours before 12 C 6þ radiation. 12 C 6þ radiation inhibited the viability of HeLa cells in a time-dependent manner, and inhibiting Wnt signalling using XAV939 significantly intensified this stress. Meanwhile, 12 C 6þ radiation induced a significant increased cell apoptosis, G2/M phase arrest, and the number of c-H2AX foci. Supplementation with XAV939 significantly increased the effects induced by 12 C 6þ radiation alone. Combining XAV939 with 12 C 6þ irradiation, the expression of apoptotic genes (p53, Bax, Bcl-2) was significantly increased, while the expression of Wnt-related genes (Wnt3a, Wnt5a, b-catenin, cyclin D1 and c-Myc) was significantly decreased. Overall, these findings suggested that blockage of the Wnt/b-catenin pathway effectively sensitizes HeLa cells to 12 C 6þ irradiation, and it may be a potential therapeutic approach in terms of increasing the clinical efficacy of 12 C 6þ beams.

show abstract

“…Inhibitors of the enzymes involved in this repair may be candidate radiosensitizers to high‐LET radiation therapy. Ataxia telangiectasia and Rad3‐related (ATR) protein inhibitor VE‐821, activator of ataxia telangiectasia‐mutated (ATM) adenosine monophosphate kinase (AMPK)‐p53/p21 metformin, nonhomologous end‐joining repair inhibitor NU7026, Wee‐1 inhibitor MK‐1775, carboplatin and paclitaxel, HSP90 inhibitor PU‐H71, and mTOR inhibitor rapamycin have been reported to improve the efficacy of carbon ion therapy.…”

Section: Particle Radiotherapy Using Proton and Carbon Ionsmentioning

confidence: 99%

“…Therefore, in order to improve the efficacy of BNCT, it is necessary to develop sensitizers targeting TP53 mutation, DNA repair, and cell cycles, referring to studies of carbon ion beams. These reagents include VE‐821, metformin, NU7026, MK‐1775, carboplatin and paclitaxel, PU‐H71, and rapamycin …”

Section: Boron Neutron Capture Therapymentioning

confidence: 99%

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Yura

Tada

Fujita

et al. 2019

Oral Science International

View full text Add to dashboard Cite

Malignant tumors such as squamous cell carcinoma (SCC), malignant salivary gland tumor, mucosal melanoma, sarcoma, and lymphoma occur in the oral cavity. Among them, oral SCC accounts for 90%. The frequency of lymph node metastasis of oral SCC varies depending on the site of occurrence, which affects the prognosis. Surgery is the primary treatment for oral cancer, but when the tumor extends, postoperative radiation with or without chemotherapy is required. Photons including X-rays and γ-rays are the most widely used types of ionizing radiation in cancer radiotherapy. Particle radiotherapy using protons and carbon ions shows a highly focused dose distribution to tumor tissues. Carbon ion therapy is effective for salivary gland tumors, malignant melanomas, and sarcomas which are less susceptible to photons. Furthermore, boron neutron capture therapy with tumor selectivity is expected to further reduce damage to surrounding normal cells. The introduction of novel radiotherapy to current treatment might improve the prognosis of patients and organ preservation. K E Y W O R D S chemotherapy, oral cancer, particle radiotherapy, radiotherapy, surgery How to cite this article: Yura Y, Tada S, Fujita Y, Hamada M. Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients. Oral Sci Int. 2019;16:49-68. https://doi.

show abstract

Radiosensitizing effect of carboplatin and paclitaxel to carbon-ion beam irradiation in the non-small-cell lung cancer cell line H460

Cited by 29 publications

References 36 publications

Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001)

Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001)

Inhibition of Wnt signalling pathway by XAV939 enhances radiosensitivity in human cervical cancer HeLa cells

Current treatment, particle radiotherapy, and boron neutron capture therapy for advanced oral cancer in patients

Contact Info

Product

Resources

About